Home -> Law Blog Directory -> Patent Law Blogs -> IPBiz
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: IPBizRanbaxy, AstraZeneca settle over Nexium
By Lawrence B. Ebert, Esq.
The WSJ reported:
The settlement means that Ranbaxy will be able to begin selling a generic version of Nexium from May 27, 2014. "Under the settlement agreement, Ranbaxy concedes that all six patents asserted by AstraZeneca in the patent litigation are valid and enforceable," said AstraZeneca in a statement. "Ranbaxy also accepts that four of the patents would be infringed by the unlicensed sale of Ranbaxy's proposed generic product."
Full post as published by IPBiz on April 15, 2008 (boomark / email).
Plavix and Nexium
A Potentially Dangerous Combination
FDA
Halts Importation of Drugs Manufactured Offshore By Ranbaxy
Verizon To Pay $52 Million To Settle
Verizon To Pay $52 Million To Settle "Pay as You Go" Data Charges FCC Investigation
Disabilities Groups Settle with Caltrans for $1.1 Billion
Disabilities Groups Settle with Caltrans for $1.1 Billion
Bayer to Pay $3.3 Million To Settle One A Day Vitamin Claims
Bayer to Pay $3.3 Million To Settle One A Day Vitamin Claims
Two Energy Companies Settle Whistleblower Qui Tam Suit
Two Energy Companies Settle Whistleblower Qui Tam Suit

AstraZeneca settles Nexium dispute with Ranbaxy Laboratories
AstraZeneca PLC Soars on Nexium Drug Patent Settlement
Nexium/Prilosec Antitrust Decision
Pfizer Wins Dismissal of Ranbaxy's Counterclaims in Caduet Patent Litigation
Jury orders AstraZeneca to pay $215 million for price inflations








